Antineoplastic drug contamination of surfaces throughout the hospital medication system in canadian hospitals

Journal of Occupational and Environmental Hygiene

Volumn 10, Issue 7, 2013, Pages 374-383

  Hon, Chun Yip ^a,b   Teschke, Kay ^a   Chu, Winnie ^a   Demers, Paul ^c   Venners, Scott ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RYERSON UNIVERSITY   (Canada)

^c Occupational Cancer Research Centre   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Antineoplastic drugs; Cyclophosphamide; Determinants; Health care; Surface contamination

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE;

ARTICLE; CANADA; HOSPITAL; HOSPITAL ORGANIZATION; OCCUPATIONAL EXPOSURE; STATISTICAL MODEL; WORKPLACE;

ANTINEOPLASTIC AGENTS; CANADA; CYCLOPHOSPHAMIDE; HOSPITALS; LINEAR MODELS; MEDICATION SYSTEMS, HOSPITAL; OCCUPATIONAL EXPOSURE; WORKPLACE;

EID: 84880105051     PISSN: 15459624     EISSN: 15459632     Source Type: Journal    
DOI: 10.1080/15459624.2013.789743     Document Type: Article

References (42)

1. Acampora, A., L. Castiglia, N. Miraglia, et al.: A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann. Occup. Hyg. 49(7):611-618 (2005
2. Connor, T.H., D.G. DeBord, J.R. Pretty, et al.: Evaluation of antineoplastic drug exposure of health care workers at three universitybased US cancer centers. J. Occup. Environ. Med. 52(10):1019-1027 (2010
3. Hedmer, M., H. Tinnerberg, A. Axmon, and B.A.G. Joensson: Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int. Arch. Occup. Environ. Health 81(7):899-911 (2008
4. Siderov, J., S. Kirsa, and R. McLauchlan: Surface contamination of cytotoxic chemotherapy preparation areas in Australian hospital pharmacy departments. J. Pharm. Pract. Res. 39(2):117 (2009
5. Turci, R., C. Sottani, G. Spagnoli, and C. Minoia: Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789(2):169-209 (2003
6. Fransman,W., R. Vermeulen, and H. Kromhout: Occupational dermal exposure to cyclophosphamide in Dutch hospitals: A pilot study. Ann Occup Hyg. 48(3):237-244 (2004
7. Dranitsaris,G., M. Johnston, S. Poirier, et al.: Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J. Oncol. Pharm. Pract. 11(2):69-78 (2005
8. Ritchie, M.A., C. McAdams, and N. Fritz: Exposure risk in the handling and administration of chemotherapy agents: A review and synthesis of the literature. Online J. Knowl. Synth. Nurs. (Feb. 2) 7:4 (2000
9. Connor, T.H., and M.A. McDiarmid: Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J. Clin. 56(6):354-365 (2006
10. Connor, T.H., R.W. Anderson, P.J. Sessink, L. Broadfield, and L.A. Power: Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am. J. Health Syst. Pharm. 56(14):1427-1432 (1999
11. "Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings." Available at http://www.cdc.gov/ niosh/docs/2004-165/(accessed November 30, 2011
12. Schulz, H., S. Bigelow, R. Dobish, and C.R. Chambers: Antineoplastic agent workplace contamination study: The Alberta Cancer Board Pharmacy perspective. J. Oncol. Pharm Pract. 11(3):101-109 (2005
13. Bigelow, S., H. Schulz, R. Dobish, and C.R. Chambers: Antineoplastic agent workplace contamination study: The Alberta Cancer Board Pharmacy perspective Phase III. J. Oncol. Pharm. Pract. 15(3):157-160 (2009
14. Bussieres, J-F., Y. Theoret, S. Prot-Labarthe, and D. Larocque: Program to monitor surface contamination by methotrexate in a hematologyoncology satellite pharmacy. Am. J. Health Syst. Pharm. 64(5):531-535 (2007
15. Touzin, K., J.F. Bussieres, E. Langlois, and M. Lefebvre: Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J. Oncol. Pharm. Pract. 15(1):53-61 (2009
16. Chu,W.C., C-Y. Hon,Q. Danyluk, P.P.S. Chua, and G. Astrakianakis: Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J. Oncol. Pharm. Pract. 18(1):46-51 (2012
17. Garlantezec, P.L., N. Rizzo-Padoin, V. Lamand, O. Auṕee, H. Broto, and D. Alḿeras: Manipulation des ḿedicaments anticanćereux á l'ĥopital: le point sur l'exposition et sur les mesures de pŕevention [Handling of antineoplastic drugs in the hospital: Focus on exposure and on protective measures]. Archives des Maladies Professionnelles et de l'Environnement 72(1):24-35 (2011). [In French]
18. Hon, C-Y., K. Teschke, P. Chua, S. Venners, and L. Nakashima: Occupational exposure to antineoplastic drugs: Identification of job categories potentially exposed throughout the hospital medication system. Saf. Health Work 2:273-281 (2011
19. Suspiro, A., and J. Prista: Biomarkers of occupational exposure do anticancer agents: A mini-review. Toxicol. Lett. 207(1):42-52 (2011
20. Helsel, D.: Much ado about next to nothing: Incorporating nondetects in science. Ann. Occup. Hyg. 54(3):257-262 (2009
21. Hornung, R., and L. Reed: Estimation of average concentration in the presence of nondetectable values. Am. Ind. Hyg. Assoc. J. 5:46-51 (1990
22. Yoshida, J., S. Koda, S. Nishida, T. Yoshida, K. Miyajima, and S. Kumagai: Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J. Oncol. Pharm. Pract. 17(1):29-38 (2011
23. Mason, H.J., S. Blair, C. Sams, et al.: Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann. Occup. Hyg. 49(7):603-610 (2005
24. Fransman, W., R. Vermeulen, and H. Kromhout: Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int. Arch. Occup. Environ Health 78(5):403-412 (2005
25. Schierl, R., A. Bohlandt, and D. Nowak: Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann. Occup. Hyg. 53(7):703-711 (2009
26. Martins, I., P. Apostoli, R. Della, and V. Henrique: Cyclophosphamide levels in sites of preparation and administration of antineoplastic drugs. Lat. Am. J. Pharm. 27(2):217-223 (2008
27. Schmaus, G., R. Schierl, and S. Funck: Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am. J. Health Syst. Pharm. 59(10):956-961 (2002
28. Sottani, C., B. Porro, M. Imbriani, and C. Minoia: Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicol. Lett. 213(1):107-115 (2011
29. Hedmer, M., P. Hoglund, E. Cavallin-St°ahl, M. Albin, and B.A.G. Jonsson: Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients. Int. Arch. Occup. Environ. Health 81(3):285-293 (2008
30. Connor, T.H., P.J.M. Sessink, B.R. Harrison, et al.: Surface contamination of chemotherapy drug vials and evaluation of new vialcleaning techniques: Results of three studies. Am. J. Health Syst. Pharm. 62(5):475-484 (2005
31. Schierl, R., A. Herwig, A. Pfaller, S. Groebmair, and E. Fischer: Surface contamination of antineoplastic drug vials: Comparison of unprotected and protected vials. Am. J. Health Syst. Pharm. 67(6):428-429 (2010
32. Hedmer, M., A. Georgiadi, E.R. Bremberg, B.A.G. Jonsson, and S. Eksborg: Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann. Occup. Hyg. 49(7):629-637 (2005
33. Sessink, P.J., and R.P. Bos: Drugs hazardous to healthcare workers. Evaluation of methods formonitoring occupational exposure to cytostatic drugs. Drug Saf. 20(4):347-359 (1999
34. Crauste-Manciet, S., P.J. Sessink, S. Ferrari, J.Y. Jomier, and D. Brossard: Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann. Occup. Hyg. 49(7):619-628 (2005
35. Stellman, J.M.: The spread of chemotherapeutic agents at work: Assessment through simulation. Cancer Invest. 5(2):75-81 (1987
36. Nygren, O., B. Gustavsson, and R. Eriksson: A test method for assessment of spill and leakage from drug preparation systems. Ann. Occup. Hyg. 49(8):711-718 (2005
37. Sessink, P.J., K.A. Boer, A.P. Scheefhals, R.B. Anzion, and R.P. Bos: Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int. Arch. Occup. Environ. Health 64(2):105-112 (1992
38. Turci, R., C. Minoia, C. Sottani, et al.: Occupational exposure to antineoplastic drugs in seven Italian hospitals: The effect of quality assurance and adherence to guidelines. J. Oncol. Pharm. Pract. 17(4):320-332 (2011
39. Touzin, K., J.F. Bussieres, E. Langlois, M. Lefebvre, and A. Metra: Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide. Ann. Occup. Hyg. 54(3):351-359 (2010
40. Sugiura, S., M. Asano, K. Kinoshita, M.Tanimura, andT. Nabeshima: Risks to health professionals from hazardous drugs in Japan: A pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J. Oncol. Pharm. Pract. 17(1):14-19 (2011
41. Barzan, C.V.: "Towards the Reduction of Occupational Exposure to Cytotoxic Drugs." Available at https://circle.ubc.ca/handle/2429/29487 (accessed August 5, 2011
42. Hama, K., K. Fukushima, M. Hirabatake, T. Hashida, and K. Kataoka: Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling. J. Oncol. Pharm. Pract. 18(2):201-206 (2012).